Reviews of the preclinical literature describe effects across skin and other connective tissues, although much of this evidence comes from cellular or animal models rather than controlled human treatment trials.[5] What the human skin evidence for GHK-Cu actually shows The published human evidence for topical GHK-Cu is limited
It's relatively affordable and available as tablets, capsules, ODTs, or combined with topiramate (Qsymia)
A study protocol, cosmetic product label, or registered trial design describes research conditions, while personal medical decisions require clinician review of risks, diagnosis, alternatives, and regulatory status [7], [8]
GHK-Cu is not an FDA-approved drug, and microneedling results vary from person to person
Blood sugar Cagrilintides relevance to blood-sugar regulation is indirect and comes from its influence on meal timing, gastric emptying, and postprandial signaling